TY - JOUR
T1 - Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome
T2 - Retrospective analysis of 157 patients from a referral cancer center
AU - Geller, Shamir
AU - Lebowitz, Emily
AU - Pulitzer, Melissa P.
AU - Horwitz, Steven M.
AU - Moskowitz, Alison J.
AU - Dusza, Steve
AU - Myskowski, Patricia L.
N1 - Publisher Copyright:
© 2019 American Academy of Dermatology, Inc.
PY - 2020/8
Y1 - 2020/8
N2 - Background: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. Objective: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. Methods: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. Results: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P =.002) and progression-free survival (P =.014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. Limitations: A retrospective study at a single cancer center. Conclusion: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.
AB - Background: The prevalence of mycosis fungoides/Sézary syndrome (MF/SS) is higher in the black population than in the white population in the United States and worse outcomes have been observed in black patients. Objective: To describe the outcomes and to identify prognostic factors in African American and black patients with MF/SS. Methods: Clinical features and follow-up data were analyzed in 157 self-identified African American or black patients seen during 1994-2018. Results: We included 122 patients with early stage MF and 35 patients with advanced-stage disease (median follow-up of 25 months). Overall, >80% of the patients who died from disease or progressed had erythema or hyperpigmentation without hypopigmentation. Patients with hypopigmentation, either as the sole manifestation or in combination with other lesions, had better overall survival (P =.002) and progression-free survival (P =.014). Clinical stage, TNMB classification, plaque disease, and elevated serum lactate dehydrogenase were also significantly associated with outcomes. Demographic and socioeconomic parameters were not associated with prognosis. Limitations: A retrospective study at a single cancer center. Conclusion: MF/SS manifestations and outcomes in African American and black patients are heterogeneous. Demographic and socioeconomic factors do not seem to have a prognostic role, while clinical characteristics might help in the stratification of risk of progression and shorter survival, allowing for individually tailored therapeutic interventions.
KW - African American
KW - MF
KW - cutaneous lymphoma
KW - hyperpigmented MF
KW - hypopigmented MF
KW - racial disparity
KW - skin of color
KW - survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85078848521&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.08.073
DO - 10.1016/j.jaad.2019.08.073
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31499157
AN - SCOPUS:85078848521
SN - 0190-9622
VL - 83
SP - 430
EP - 439
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -